Literature DB >> 11032838

The proteasome regulates receptor-mediated endocytosis of interleukin-2.

A Yu1, T R Malek.   

Abstract

Recent studies have increasingly implicated the proteasome in the regulation of cell surface receptors. In the present study, we investigated the role of the proteasome for ligand-dependent endocytosis and degradation of the interleukin-2 (IL-2)-interleukin-2 receptor (IL-2R) complex. Proteasome inhibitors impaired internalization of IL-2.IL-2R and prevented the lysosomal degradation of this cytokine. Based on time-course studies, proteasome activity is primarily required after initial endocytosis of the IL-2.IL-2R. Proteasome function was also necessary for the lysosomal degradation of IL-2 internalized by IL-2R that were comprised of cytoplasmic tailless beta- or gamma c-subunits, suggesting that the target protein for the proteasome is independent of either the cytoplasmic tail of the IL-2R beta- or gamma c-subunits and their associated signaling components. Therefore, a functional proteasome is required for optimal endocytosis of the IL-2R/ligand complex and is essential for the subsequent lysosomal degradation of IL-2, possibly by regulating trafficking to the lysosome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11032838     DOI: 10.1074/jbc.M007991200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization.

Authors:  M Martinez-Moczygemba; D P Huston
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins.

Authors:  P van Kerkhof; C M Alves dos Santos; M Sachse; J Klumperman; G Bu; G J Strous
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

Review 3.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

4.  A protein interaction network for Ecm29 links the 26 S proteasome to molecular motors and endosomal components.

Authors:  Carlos Gorbea; Gregory Pratt; Vicença Ustrell; Russell Bell; Sudhir Sahasrabudhe; Robert E Hughes; Martin Rechsteiner
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

5.  14-Deoxyandrographolide desensitizes hepatocytes to tumour necrosis factor-alpha-induced apoptosis through calcium-dependent tumour necrosis factor receptor superfamily member 1A release via the NO/cGMP pathway.

Authors:  D N Roy; S Mandal; G Sen; S Mukhopadhyay; T Biswas
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

6.  Regulation of nicotinic receptor expression by the ubiquitin-proteasome system.

Authors:  John C Christianson; William N Green
Journal:  EMBO J       Date:  2004-10-14       Impact factor: 11.598

7.  Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.

Authors:  Roberta Schiavo; Dolgor Baatar; Purevdorj Olkhanud; Fred E Indig; Nicholas Restifo; Dennis Taub; Arya Biragyn
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

8.  Degradation of retinoid X receptor alpha by TPA through proteasome pathway in gastric cancer cells.

Authors:  Xiao-Feng Ye; Su Liu; Qiao Wu; Xiao-Feng Lin; Bing Zhang; Jia-Fa Wu; Ming-Qing Zhang; Wen-Jin Su
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells.

Authors:  Juu-Chin Lu; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2005-08-15       Impact factor: 5.157

10.  Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator.

Authors:  Martina Gentzsch; Xiu-Bao Chang; Liying Cui; Yufeng Wu; Victor V Ozols; Amit Choudhury; Richard E Pagano; John R Riordan
Journal:  Mol Biol Cell       Date:  2004-04-09       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.